Serbousek Jon Carl

SEC source: 0001209191-23-023445 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,827

F1 · balance_after: Includes 268,554 previously reported unvested restricted stock units.

SEC source: 0001209191-23-007203 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 352,968

F1 · balance_after: Includes 287,130 shares of unvested restricted stock units.

SEC source: 0001209191-23-002660 · doc4.xml · nonDerivative · entry 3

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,110

F3 · shares: Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025.

F4 · balance_after: Includes 307,621 unvested restricted stock units.

SEC source: 0001209191-23-002660 · doc4.xml · nonDerivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,143

F2 · shares: Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024.

SEC source: 0001209191-23-002660 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,379

F1 · shares: Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023.

SEC source: 0001209191-23-002662 · doc4.xml · nonDerivative · entry 3

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,110

F3 · shares: Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025.

F4 · balance_after: Includes 307,621 unvested restricted stock units.

SEC source: 0001209191-23-002662 · doc4.xml · nonDerivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,143

F2 · shares: Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024.

SEC source: 0001209191-23-002662 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,379

F1 · shares: Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023.

SEC source: 0001209191-22-055521 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,551

SEC source: 0001209191-22-045058 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,920

SEC source: 0001209191-22-023339 · doc4.xml · nonDerivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,839

SEC source: 0001209191-22-023339 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,880

SEC source: 0001209191-22-006835 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

F2 · derivative.expiration_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

SEC source: 0001209191-22-006835 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,779

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.

SEC source: 0001209191-21-065552 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,812

SEC source: 0001209191-21-062275 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,903

SEC source: 0001209191-21-050298 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,272

SEC source: 0001209191-21-025402 · doc4.xml · derivative · entry 3

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,764

Underlying: Common Stock · 40,764 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F2 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-21-025402 · doc4.xml · nonDerivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,722

SEC source: 0001209191-21-025402 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,506

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2021.

SEC source: 0001209191-20-056465 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,181

SEC source: 0001209191-20-046214 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,647

SEC source: 0001209191-20-035636 · doc4.xml · derivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,872

Underlying: Common Stock · 45,872 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F1 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-20-023302 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,372

Underlying: Common Stock · 107,372 shares

Expires 2030-04-01

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-023302 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,266

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-014262 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,728

F1 · shares: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.23 to $35.50, inclusive. The reporting person undertakes to provide Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-19-055270 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,449

Underlying: Common Stock · 81,449 shares

Expires 2029-11-01

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, November 1, 2019.

SEC source: 0001209191-19-055270 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,828

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, November 1, 2019.

SEC source: 0001209191-19-044717 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,711

Underlying: Common Stock · 50,711 shares

Expires 2029-08-05

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, August 5, 2019.

SEC source: 0001209191-19-044717 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,743

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, August 5, 2019.